Core Insights - DexCom, Inc. (NASDAQ:DXCM) is recognized as one of the top 10 healthcare equipment stocks favored by hedge funds [1] - Analysts have provided mixed price target adjustments, reflecting confidence in the company's performance and future potential [2][3] Group 1: Analyst Ratings and Price Targets - William Plovanic from Canaccord Genuity reduced the price target on DexCom from $99 to $95 while maintaining a Buy rating [1] - Jeff Johnson from Baird reaffirmed an Outperform rating and raised the price target from $82 to $87, indicating an upside potential of nearly 20% [3] Group 2: Company Strategy and Product Focus - The company's fourth-quarter results and 2026 outlook met expectations, with a consistent strategy focused on product refinements in the U.S. market to maintain leadership in glucose sensors [2] - DexCom plans to introduce tiered sensor solutions internationally and is working to enhance insurance coverage for continuous glucose monitoring (CGM) [2] Group 3: Product Offerings - DexCom specializes in continuous glucose monitoring systems that help manage diabetes and metabolic conditions by tracking glucose levels [4] - Key products include DexCom G6, DexCom G7, DexCom Share, DexCom Real-Time API, and DexCom ONE [4]

Core Insights - DexCom Inc (NASDAQ:DXCM) is recognized as one of the top 12 medical device stocks favored by hedge funds, with a strong bullish sentiment reflected in analyst ratings [1] - The company reported fourth-quarter results with U.S. revenues of $892 million and international revenues of $368 million, achieving year-over-year growth of 11% and 18% respectively, surpassing consensus estimates by nearly 2 percentage points [2] - For FY 2025, management anticipates an adjusted gross margin of approximately 61% and an adjusted operating margin of around 20%-21%, with projected revenues for 2026 between $5.16 billion and $5.25 billion [3] Company Overview - DexCom Inc specializes in continuous glucose monitoring (CGM) systems that assist in managing diabetes and metabolic conditions by providing real-time glucose level tracking [4]